KR100617485B1 - 파필로마바이러스 감염의 치료 - Google Patents

파필로마바이러스 감염의 치료 Download PDF

Info

Publication number
KR100617485B1
KR100617485B1 KR1020017007244A KR20017007244A KR100617485B1 KR 100617485 B1 KR100617485 B1 KR 100617485B1 KR 1020017007244 A KR1020017007244 A KR 1020017007244A KR 20017007244 A KR20017007244 A KR 20017007244A KR 100617485 B1 KR100617485 B1 KR 100617485B1
Authority
KR
South Korea
Prior art keywords
vlps
therapeutic vaccine
infection
hpv
hpv11
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017007244A
Other languages
English (en)
Korean (ko)
Other versions
KR20010103711A (ko
Inventor
시아오 이 썬
이안 프래저
지안 조우
Original Assignee
더 유니버서티 어브 퀸슬랜드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버서티 어브 퀸슬랜드 filed Critical 더 유니버서티 어브 퀸슬랜드
Publication of KR20010103711A publication Critical patent/KR20010103711A/ko
Application granted granted Critical
Publication of KR100617485B1 publication Critical patent/KR100617485B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020017007244A 1998-12-11 1999-12-13 파필로마바이러스 감염의 치료 Expired - Fee Related KR100617485B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP7653 1998-12-11
AUPP7653A AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections

Publications (2)

Publication Number Publication Date
KR20010103711A KR20010103711A (ko) 2001-11-23
KR100617485B1 true KR100617485B1 (ko) 2006-09-01

Family

ID=3811858

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017007244A Expired - Fee Related KR100617485B1 (ko) 1998-12-11 1999-12-13 파필로마바이러스 감염의 치료

Country Status (12)

Country Link
US (2) US6867033B1 (cg-RX-API-DMAC7.html)
EP (1) EP1144005B1 (cg-RX-API-DMAC7.html)
JP (2) JP5274737B2 (cg-RX-API-DMAC7.html)
KR (1) KR100617485B1 (cg-RX-API-DMAC7.html)
AT (1) ATE344053T1 (cg-RX-API-DMAC7.html)
AU (1) AUPP765398A0 (cg-RX-API-DMAC7.html)
CA (1) CA2353866C (cg-RX-API-DMAC7.html)
DE (1) DE69933891T2 (cg-RX-API-DMAC7.html)
DK (1) DK1144005T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ512850A (cg-RX-API-DMAC7.html)
WO (1) WO2000035478A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA997638B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284287T3 (es) * 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
FR2802426B1 (fr) * 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US10513541B2 (en) 2015-12-04 2019-12-24 Xiamen University Mutant of L1 protein of human papillomavirus type 11
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1359156B1 (en) 1991-07-19 2007-03-07 University of Queensland Vaccine against Human Papillomavirus (Type 18)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
ES2264126T3 (es) * 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
DE69531256T2 (de) * 1994-09-06 2004-05-27 Scan-Web I/S Verfahren und system zur herstellung von breiten, luftgelegten papierbahnen enthaltend ein absorbierendes pulver
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
AU4258297A (en) 1996-09-11 1998-04-02 Merck & Co., Inc. Papillomavirus vaccine formulation
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2273376T3 (es) 1996-12-20 2007-05-01 MERCK & CO., INC. Formulaciones de vacunas recombinantes frente a papilomas.
WO1998044944A2 (en) * 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
DE19735118C1 (de) 1997-08-13 1998-08-13 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Also Published As

Publication number Publication date
NZ512850A (en) 2004-01-30
KR20010103711A (ko) 2001-11-23
JP2002532434A (ja) 2002-10-02
JP2011037902A (ja) 2011-02-24
ATE344053T1 (de) 2006-11-15
DK1144005T3 (da) 2007-03-05
US7172870B2 (en) 2007-02-06
WO2000035478A1 (en) 2000-06-22
CA2353866C (en) 2013-11-19
JP5274737B2 (ja) 2013-08-28
US20050244433A1 (en) 2005-11-03
ZA997638B (en) 2000-07-06
CA2353866A1 (en) 2000-06-22
DE69933891D1 (de) 2006-12-14
US6867033B1 (en) 2005-03-15
EP1144005A4 (en) 2005-02-09
EP1144005A1 (en) 2001-10-17
DE69933891T2 (de) 2007-06-21
AUPP765398A0 (en) 1999-01-14
EP1144005B1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
Zhang et al. HPV6b virus like particles are potent immunogens without adjuvant in man
Brun et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy
Kaufmann et al. Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3)
Corona Gutierrez et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus
Baldwin et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia
JP2011037902A (ja) パピローマウイルス感染の治療方法
JP2004535816A (ja) Cinを含むhpv関連の前癌性増殖および癌性増殖に関する方法および組成物
KR100777896B1 (ko) 성인성질환에 대한 백신
US20150098959A1 (en) Mucosal Immunity-Stimulating Agent, and Oral Pharmaceutical Composition for Treating HPV Infection
JP4854742B2 (ja) 抗hpv感染症薬の調製におけるノカルディア・ルブラ細胞壁骨格の使用
KR101359943B1 (ko) Hpv 16과 hpv 18 및 적어도 hpv 31, 45 또는 52로부터 선택된 또 다른 hpv 유형에 대한 백신
RU2420313C2 (ru) Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52
AU762114B2 (en) Treatment of papillomavirus infections
KR20080005585A (ko) 백신
US20080089910A1 (en) Attenuated Herpes Simplex Virus Type-2, Vectors Thereof and Immunogenic Compositions Thereof
Gonçalves et al. Safety, Efficacy, and Immunogenicity of Therapeutic Vaccines for Patients with High-Grade Cervical Intraepithelial Neoplasia (Cin 2/3) Associated with Human Papillomavirus: A Systematic Review and Meta-Analysis
Kyuregyan et al. UNIVERSAL SINGLE-DOSE VACCINATION AGAINST HEPATITIS A
HK1100533B (en) Use of nocardia rubra cell wall skeleton to produce medicaments for resisting human papilloma virus hpv
KR20080005583A (ko) 백신
Hirnle et al. Vaccines Against HPV of the Uterine Cervix: Problems in Clinical Applicability

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20120802

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20130731

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20140729

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20150730

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20160805

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20170728

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190823

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190823

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000